Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Etanercept

4

XV.e Path: ILD with a granulomatous component (see also Im)

2
Last update : 07/10/2012
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist
See also under
TNF-alpha antagonists / inhibitors
5

Publications

Pulmonary Sarcoidosis following Etanercept Treatment.
Case reports in rheumatology 2012;2012;724013 2012
Development of sarcoidosis during etanercept therapy.
Internal medicine (Tokyo, Japan) 2008;47;1021-5 2008
Pulmonary lymphohistiocytic reactions temporally related to etanercept therapy.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2005 May;18;651-5 2005 May
Lung injury linked to etanercept therapy.
Chest 2002 Nov;122;1858-60 2002 Nov

Powered by

  • ^
  • Contact
  • Cookies
  • About

The Pneumotox website uses cookies. By accessing or using our website, you consent to the collection, use and disclosure of the garnered information in accordance with our privacy policy.

Learn more about cookies